Samantha Bellinger
Family · Oklahoma City, OKNPI 1275902900
Payments from drug & device makers
Across 1,084 payments — averaging $36.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$17K
- AstraZeneca$4K
- Regeneron Healthcare Solutions, Inc.$4K
- Boehringer Ingelheim$2K
- GSK$2K
- Insmed, Inc.$2K
- plus $8K from 30 others
What the payments were for
- Consulting fees$7,50119%
- Speaking & faculty fees$4,98813%
- Travel & lodging$2,7367%
- Food & beverage$23,76460%
- Education$4351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 104 | $17,426 |
| AstraZeneca(2 entities) | 183 | $4,451 |
| Regeneron Healthcare Solutions, Inc. | 57 | $3,753 |
| Boehringer Ingelheim | 95 | $1,980 |
| GSK | 145 | $1,930 |
| Insmed, Inc. | 76 | $1,514 |
| Baxter Healthcare | 40 | $849 |
| Amgen | 52 | $824 |
| Actelion Pharmaceuticals US, Inc. | 30 | $816 |
| Mylan Specialty L.p. | 57 | $780 |
| United Therapeutics Corporation | 25 | $711 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $655 |
| Pulmonx Corporation | 18 | $441 |
| Genentech USA, Inc. | 23 | $431 |
| Novartis | 16 | $348 |
| Gilead | 19 | $346 |
| Merck | 11 | $281 |
| Verona Pharma, Inc. | 19 | $226 |
| Grifols USA, LLC | 8 | $176 |
| Viatris Specialty LLC | 13 | $161 |
| Inspire Medical Systems, Inc. | 4 | $158 |
| Teva Pharmaceuticals USA, Inc. | 8 | $144 |
| Johnson & Johnson(2 entities) | 8 | $142 |
| Sanofi-aventis U.S. LLC | 3 | $136 |
| Pfizer | 7 | $123 |
| Philips North America LLC | 6 | $111 |
| Advanced Respiratory, Inc | 3 | $95 |
| Electromed, Inc. | 8 | $95 |
| Lilly USA, LLC | 4 | $86 |
| Inogen, Inc. | 6 | $76 |
| Fisher & Paykel Healthcare Inc | 3 | $61 |
| AbbVie | 1 | $34 |
| Nabriva Therapeutics, PLC | 1 | $18 |
| Sanofi US Services Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| ANI Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,423 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 514 | $392,648 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 285 | $211,592 |
| Breo ElliptaFluticasone/Vilanterol | 413 | $191,975 |
| OfevNintedanib Esylate | 13 | $167,391 |
| HyqviaIgg/Hyaluronidase,recombinant | 13 | $75,343 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 116 | $55,029 |
| NucalaMepolizumab | 12 | $45,148 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 51 | $40,854 |
| SymbicortBudesonide/Formoterol Fumarate | 83 | $25,975 |
| Advair HfaFluticasone Propion/Salmeterol | 56 | $24,022 |
| Arnuity ElliptaFluticasone Furoate | 61 | $20,116 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 148 | $19,520 |
| Spiriva RespimatTiotropium Bromide | 29 | $18,185 |
| Incruse ElliptaUmeclidinium Bromide | 39 | $17,289 |
| DuleraMometasone/Formoterol | 37 | $15,567 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala, Arnuity Ellipta | $1,930 | $722,2061,155 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $4,451 | $237,566368 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,980 | $235,890108 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $655 | $75,34313 claims |
| MerckDulera | $281 | $15,56737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.
Other family in Oklahoma City
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Lacey HillOklahoma City$20K
- Julia John SamuelOklahoma City$17K
- Kristina SnyderOklahoma City$15K
- Lindi CiglarOklahoma City$15K
- Shymol JohnOklahoma City$14K
- Xiomara PorrasOklahoma City$12K
- Anne DudeOklahoma City$11K
- Kailee AndersonOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.